中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 8
Aug.  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(8): 1861-1866

Mechanism of action of GP73 in the regulation of liver cancer: An analysis based on transcriptome sequencing

DOI: 10.3969/j.issn.1001-5256.2021.08.022
  • 1.

    Department of Clinical Laboratory, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China

  • 2.

    Department of Clinical Laboratory, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou 510700, China

Research funding:

Medical Scientific Research Fund of Guangdong Province (A2018153);

Science and Technology Project of Guangzhou Health and Family Planning Commission (20181A011072)

  • Received Date: 2021-01-20
  • Accepted Date: 2021-04-12
  • Published Date: 2021-08-20
    Abstract
  •   Objective  To investigate the mechanism of action of GP73 in the regulation of liver cancer based on transcriptome analysis.  Methods  Hepatoma Hep3B cells were divided into GP73 interference group, GP73 interference control group, GP73 overexpression group, and GP73 overexpression control group, and transcriptome sequencing was used to measure mRNA expression in the four groups. Differentially expressed genes were screened out based on sequencing data and were then analyzed by GO functional analysis and KEGG enrichment analysis. Western blot was used to verify the expression of signaling pathway-related proteins. The t-test was used for comparison of normally distributed continuous data between groups.  Results  The differentially expressed genes in Hep3B cells were analyzed after GP73 interference and overexpression. GO analysis revealed 586 biological processes, and GP73 was mainly involved in the processes such as cellular process, single-organism process, and biological regulation. KEGG analysis showed that GP73 was mainly involved in the signaling pathways closely associated with liver cancer, including the PI3K-AKT signaling pathway, the cytokine-cytokine receptor interaction signaling pathway, the TNF signaling pathway, and the JAK-STAT signaling pathway. Western blot was used to verify the three proteins PI3K, p-Akt, and Akt in the PI3K-AKT signaling pathway, and the results showed that there were significant differences in the expression of PI3K and p-Akt between the GP73 interference group and the GP73 interference control group and between the GP73 overexpression group and the GP73 overexpression control group (all P < 0.05).  Conclusion  The signaling pathways involving GP73 in the regulation of liver cancer are screened out by transcriptome sequencing and bioinformatics analysis, which provides new ideas for further elucidating the mechanism of action of GP73 in liver cancer.

     

    • FullText(HTML)
  • loading
    • References(12)
  • [1]
    PETRICK JL, FLORIO AA, ZNAOR A, et al. International trends in hepatocellular carcinoma incidence, 1978-2012[J]. Int J Cancer, 2020, 147(2): 317-330. DOI: 10.1002/ijc.32723.
    [2]
    LI JN, ZHENG RQ, LI N, et al. The biological characteristics of GP73 and its value in the diagnosis of liver fibrosis and cirrhosis[J]. J Clin Hepatol, 2019, 35(6): 1361-1364. DOI: 10.3969/j.issn.1001-5256.2019.06.040.

    李佳娜, 郑瑞琦, 李娜, 等. 高尔基体蛋白73的生物学特征及在肝纤维化和肝硬化中的诊断价值[J]. 临床肝胆病杂志, 2019, 35(6): 1361-1364. DOI: 10.3969/j.issn.1001-5256.2019.06.040.
    [3]
    XIAO J, LONG F, PENG T, et al. Development and potential application of a simultaneous multiplex assay of Golgi protein 73 and alpha-fetoprotein for hepatocellular carcinoma diagnosis[J]. Eur Rev Med Pharmacol Sci, 2019, 23(8): 3302-3310. DOI: 10.26355/eurrev_201904_17692.
    [4]
    JIAO C, CUI L, PIAO J, et al. Clinical significance and expression of serum Golgi protein 73 in primary hepatocellular carcinoma[J]. J Cancer Res Ther, 2018, 14(6): 1239-1244. DOI: 10.4103/0973-1482.199784.
    [5]
    KE MY, WU XN, ZHANG Y, et al. Serum GP73 predicts posthepatectomy outcomes in patients with hepatocellular carcinoma[J]. J Transl Med, 2019, 17(1): 140. DOI: 10.1186/s12967-019-1889-0.
    [6]
    CHEN M, ZHAO K, LIU PC, et al. Effects of silencing GP73 with siRNA interference on the migration and invasion of human hepatoma HepG2 cells[J]. J Shanghai Jiaotong Univ (Med Sci), 2016, 36(11): 1588-1593. DOI: 10.3969/j.issn.1674-8115.2016.11.009.

    陈默, 赵坤, 柳鹏程, 等. RNA干扰技术沉默GP73对人肝癌HepG2细胞迁移和侵袭的影响[J]. 上海交通大学学报(医学版), 2016, 36(11): 1588-1593. DOI: 10.3969/j.issn.1674-8115.2016.11.009.
    [7]
    KLADNEY RD, BULLA GA, GUO L, et al. GP73, a novel Golgi-localized protein upregulated by viral infection[J]. Gene, 2000, 249(1-2): 53-65. DOI: 10.1016/s0378-1119(00)00136-0.
    [8]
    YE PL, HE XX, WU XM. Expression of GP73 in liver tissue of primary liver cancer[J]. Guangdong Med J, 2014, 35(2): 234-236. DOI: 10.13820/j.cnki.gdyx.2014.02.025.

    叶佩灵, 何欣欣, 吴晓蔓. 原发性肝癌组织中GP73蛋白的表达[J]. 广东医学, 2014, 35(2): 234-236. DOI: 10.13820/j.cnki.gdyx.2014.02.025.
    [9]
    YE PL, WU XM. Significance of GP73 level in primary hepatocellular carcinoma[J]. J Hainan Med Univ, 2014, 20(1): 83-86, 89. DOI: 10.13210/j.cnki.jhmu.2014.01.033.

    叶佩灵, 吴晓蔓. 高尔基体糖蛋白73在原发性肝癌中的表达及意义[J]. 海南医学院学报, 2014, 20(1): 83-86, 89. DOI: 10.13210/j.cnki.jhmu.2014.01.033.
    [10]
    YE PL, WU XM. The significance of combined detection of serum Golgi protein 73, AFP, CEA, CA199 and GGT in the early diagnosis of primary hepatic carcinoma[J]. J Tropical Med, 2016, 16(4): 467-470.

    叶佩灵, 吴晓蔓. 血清GP73联合AFP、CEA、CA199、GGT检测在PHC早期筛查的应用价值[J]. 热带医学杂志, 2016, 16(4): 467-470.
    [11]
    YANG Y, LIU Q, LI Z, et al. GP73 promotes epithelial-mesenchymal transition and invasion partly by activating TGF-β1/Smad2 signaling in hepatocellular carcinoma[J]. Carcinogenesis, 2018, 39(7): 900-910. DOI: 10.1093/carcin/bgy010.
    [12]
    YANG Y, LIU Q, ZHANG H, et al. Silencing of GP73 inhibits invasion and metastasis via suppression of epithelial-mesenchymal transition in hepatocellular carcinoma[J]. Oncol Rep, 2017, 37(2): 1182-1188. DOI: 10.3892/or.2017.5351.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(7)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (690) PDF downloads(50) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return